Predictors of Response to Iron and Erythropoietin Stimulating Agents

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 197 participants.

Also called NCT03658876

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose diagnostic
Phase
Phase 4
Enrolled
  • 197 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03658876
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03658876. Randomized; no masking; primary purpose diagnostic. Start 2015-06-03 (actual); primary completion 2016-12-31 (actual). Results posted on 2019-07-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Predictors of Response to Iron and Erythropoietin Stimulating Agents
Acronym
PRIME
Condition
Renal Failure Chronic
Condition
Anemia
Intervention (Drug)
Iron Sucrose Solution for Injection
Intervention (Drug)
Epoetin Beta
Lead sponsor
Imperial College London (class: other)

Record details

Record id
cardio:ct-nct03658876
Content hash
6dce0ad2a2681e3336afcd782997d3f749df5530009d809a01bb0c9dba94d520